Relative bioavailability and pharmacokinetics of two oral formulations of docosahexaenoic acid/eicosapentaenoic acid after multiple-dose administration in healthy volunteers

European Journal of Clinical Pharmacology

Volumn 65, Issue 5, 2009, Pages 503-510

  Rusca, Antonio ^c   Di Stefano, Andrea Francesco Daniele ^c   Doig, Mira V ^b   Scarsi, Claudia ^a   Perucca, Emilio ^d  

^a Institut Biochimique SA   (Switzerland)

^b ABS Laboratories Ltd   (United Kingdom)

^c Cross Research SA   (Switzerland)

^d UNIVERSITY OF PAVIA   (Italy)

Author keywords

3 fatty acids; Bioavailability; Docosahexaenoic acid; Eicosapentaenoic acid; Humans

Indexed keywords

DOCOSAHEXAENOIC ACID; DOCOSAHEXAENOIC ACID PLUS EICOSAPENTAENOIC ACID; ICOSAPENTAENOIC ACID; UNCLASSIFIED DRUG;

ABDOMINAL SWELLING; ADULT; AEROPHAGIA; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BLOOD SAMPLING; CLINICAL TRIAL; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG SCREENING; EPIGASTRIC PAIN; ERUCTATION; FEMALE; GAS LIQUID CHROMATOGRAPHY; GASTROINTESTINAL DISEASE; HALITOSIS; HEARTBURN; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE DRUG DOSE; NAUSEA; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STEADY STATE; STOMACH CRAMP; STOMACH DISCOMFORT; THIRST; UPPER ABDOMINAL PAIN; VOMITING; WATERY STOOL;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CAPSULES; DOCOSAHEXAENOIC ACIDS; DOSE-RESPONSE RELATIONSHIP, DRUG; EICOSAPENTAENOIC ACID; FATTY ACIDS, OMEGA-3; FEMALE; HUMANS; MALE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REFERENCE VALUES; THERAPEUTIC EQUIVALENCY; YOUNG ADULT;

EID: 67349155571     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-008-0605-4     Document Type: Article

References (31)

1. F Piscione C Pignalberi A Totteri F Messina G Altamura 2007 Cardiovascular effects of omega-3 free Fatty acids Curr Vasc Pharmacol 5 2 163 172
2. MP Freeman JR Hibbeln KL Wisner JM Davis D Mischoulon M Peet PE Keck Jr LB Marangell AJ Richardson J Lake AL Stoll 2006 Omega-3 fatty acids: evidence basis for treatment and future research in psychiatry J Clin Psychiatry 67 12 1954 1967
3. S Lee KM Gura S Kim DA Arsenault BR Bistrian M Puder 2006 Current clinical applications of omega-6 and omega-3 fatty acids Nutr Clin Pract 21 4 323 341
4. HS Weber D Selimi G Huber 2006 Prevention of cardiovascular diseases and highly concentrated n-3 polyunsaturated fatty acids (PUFAs) Herz 31 Suppl 3 24 30
5. CH Ruxton SC Reed MJ Simpson KJ Millington 2007 The health benefits of omega-3 polyunsaturated fatty acids: a review of the evidence J Hum Nutr Diet 20 3 275 285
6. C von Schacky 2007 Omega-3 fatty acids and cardiovascular disease Curr Opin Clin Nutr Metab Care 10 2 129 135
7. K He EB Rimm A Merchant 2002 Fish consumption and risk of stroke in men JAMA 288 24 3130 3135
8. ML Burr AM Fehily JF Gilbert 1989 Effects of changes in fat, fish, and fibres intake on death and myocardial reinfarction: diet and reinfarction trial (DART) Lancet 2 757 761
9. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico 1999 Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial Lancet 354 47 55
10. MJ Gibney E Daly 1994 The incorporation of n-3 polyunsaturated fatty acids into plasma lipid and lipoprotein fractions in the postprandial phase in healthy volunteers Eur J Clin Nutr 48 866 872
11. J Hodge K Sanders AJ Sinclair 1993 Differential utilization of eicosapentaenoic acid and docosahexaenoic acid in human plasma Lipids 28 6 525 531
12. TA Marsen M Pollok K Oette 1992 Pharmacokinetics of omega-3-fatty acids during ingestion of fish oil preparations Prostaglandins Leukot Essent Fat Acids 46 3 191 196
13. F Marangoni MT Angeli S Colli 1993 Changes of n-3 and n-6 fatty acids in plasma and circulating cells of normal subjects, after prolonged administration of 20:5 (EPA) and 22:6 (DHA) ethyl esters and prolonged washout Biochim Biophys Acta 1210 1 55 62
14. HM Vidgren JJ Agren U Schwab T Rissanen O Hänninen MI Uusitupa 1997 Incorporation of n-3 fatty acids into plasma lipid fractions, and erythrocyte membranes and platelets during dietary supplementation with fish, fish oil, and docosahexaenoic acid-rich oil among healthy young men Lipids 32 7 697 705
15. J Cao KA Schwichtenberg NQ Hanson MY Tsai 2006 Incorporation and clearance of omega-3 fatty acids in erythrocyte membranes and plasma phospholipids Clin Chem 52 12 2265 2272
16. MJ Bruno RE Koeppe OS Andersen 2007 Docosahexaenoic acid alters bilayer elastic properties Proc Natl Acad Sci USA 104 23 9638 9643
17. JA Lundbaek OS Andersen 1994 Lysophospholipids modulate channel function by altering the mechanical properties of lipid bilayers J Gen Physiol 104 4 645 673
18. EK Lund LJ Harvey S Ladha DC Clark IT Johnson 1999 Effects of dietary fish oil supplementation on the phospholipid composition and fluidity of cell membranes from human volunteers Ann Nutr Metab 43 5 290 300
19. LM Arterburn EB Hall H Oken 2006 Distribution, interconversion, and dose response of n-3 fatty acids in humans Am J Clin Nutr 83 6 Suppl 1467S 1476S
20. Department of Health and Human Services and U.S. Department of Agriculture (2005) Dietary guidelines for Americans. http://www.health.gov/ DietaryGuidelines/dga2005/document/default.htm . Accessed 18 Dec 2008
21. DJ Schuirmann 1990 Design of bioavailability/bioequivalence studies Drug Inf J 24 315 323
22. The European Agency for the Evaluation of Medicinal Products (EMEA) (2001) Note for guidance on the investigation of bioavailability and bioequivalence. Guideline CPMP/EWP/QWP/1401/98. http://www.emea.europa.eu/pdfs/ human/qwp/140198en.pdf . Accessed 18 Dec 2008
23. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) (2003) Guidance for industry-bioavailability and bioequivalence studies for orally administered drug products. General considerations. http://www.fda.gov/Cder/guidance/5356fnl.htm . Accessed 18 Dec 2008
24. Food and Drug Administration, Advisory Committee for Pharmaceutical Science (2004) Briefing information: bioequivalence requirements for highly variable drugs and drug products. Washington DC
25. L Tothfalusi L Endrenyi KK Midha 2001 Evaluation of the bioequivalence of highly variable drugs and drug products Pharm Res 18 728 733
26. L Tothfalusi L Endrenyi 2003 Limits for the scaled average bioequivalence of highly variable drugs and drug products Pharm Res 20 382 389
27. max Int J Clin Pharmacol Ther 41 217 225
28. A Marzo 1999 Open questions on bioequivalence: some problems and some solutions Pharmacol Res 40 4 357 368
29. SAS/STAT user's guide, version 8.2
30. Thermo Electron (2005) Kinetica 4.4.1 user's manual. Waltham, MA
31. MC Blonk HJ Bilo JJ Nauta C Popp-Snijders C Mulder AJ Donker 1990 Dose-response effects of fish-oil supplementation in healthy volunteers Am J Clin Nutr 52 1 120 127